Browse studies

Find your next paid study

24 recruiting studies matching your filters

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an ear…

Ductal Carcinoma in Situ

Estimated

~$75 – $3,000

Actual pay is set by the research site.

QuantumLeap Healthcare CollaborativeNCT06075953

Observational

Approaches to Identify and Care for Individuals With Inherited Cancer Syndromes

This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testi…

BRCA1/2-Associated Hereditary Breast and Ovarian Cancer SyndromeBreast Ductal Carcinoma In SituHematopoietic and Lymphoid System Neoplasm+3 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

OHSU Knight Cancer InstituteNCT04494945

Phase 2

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

This study evaluates the rates of radiation-specific toxicity, quality of life, and oncologic outcomes for early-stage breast cancer and ductal carcinoma in si…

Breast CancerEarly-stage Breast CancerDuctal Carcinoma in Situ+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

UNC Lineberger Comprehensive Cancer CenterNCT06902311

Phase 2

Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. In…

Breast Atypical Ductal HyperplasiaBreast Atypical Lobular HyperplasiaBreast Carcinoma+3 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06184750

Phase 1

A Phase IB Trial of Neoadjuvant Multi-Epitope HER2 Peptide Vaccine in Patients With HER2-Expressing DCIS

This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma…

Breast Ductal Carcinoma In Situ

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Mayo ClinicNCT04144023

Phase 2

Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer

This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing…

Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In Situ+1 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT05941520

Phase 2

Ultra-Short External Beam-Based Accelerated Partial Breast Irradiation (APBI): A Phase II Toxicity Study Nested With a Non-inferiority Assessment of APBI in New Patient Cohorts

The purpose of this study is to determine if the dose of radiation therapy that is effective in producing a treatment response, delivered over a shorter treatm…

Invasive Ductal Breast CarcinomaInvasive Ductal Carcinoma, BreastDCIS+3 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT04084730

Observational

Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ

Cryoablation or tumor freezing is a percutaneous, office-based procedure that is emerging as a minimally invasive, cost-effective alternative to surgery that i…

Ductal Carcinoma in Situ

Estimated

~$10 – $750

Actual pay is set by the research site.

Glendale Adventist Medical Center d/b/a Adventist Health GlendaleNCT05218044

Phase 2

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer (BabyTEARS)

The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk f…

Breast CancerDuctal CarcinomaEstrogen-receptor-positive Breast Cancer+4 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT07499999

Phase 1

A Phase I/Ib Study Evaluating Intralesional TLR7 Agonist, CAN1012, in Pre-malignant Ductal Carcinoma in Situ and Lobular Carcinoma in Situ

This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.

Ductal Carcinoma in SituLobular Carcinoma in Situ

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Providence Health & ServicesNCT07408856

Phase 2

Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer

This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese w…

Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In Situ+1 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06195306

Potential Impact of the COVID -19 Pandemic on Financial Toxicity in Breast Cancer Surgical Patients: The Impact on Out of Pocket Costs, Lost Wages and Economic Strain

This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast s…

Breast Ductal Carcinoma In SituCOVID-19 InfectionHereditary Breast Carcinoma+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT04169542